当前位置: X-MOL 学术Clin. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes
Clinical Infectious Diseases ( IF 11.8 ) Pub Date : 2017-12-20 , DOI: 10.1093/cid/cix1106
Zobair M Younossi 1, 2 , Maria Stepanova 3 , Tarik Asselah 4 , Graham Foster 5 , Keyur Patel 6 , Norbert Bräu 7 , Mark Swain 8 , Tram Tran 9 , Rafael Esteban 10 , Massimo Colombo 11 , Stephen Pianko 12 , Linda Henry 3 , Marc Bourliere 13
Affiliation  

While the necessity of treatment of hepatitis C virus (HCV)–infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the effect of treating HCV in patients with no or minimal fibrosis (Metavir stage F0–F1) on patient-reported outcomes (PROs).

中文翻译:

最小或无肝纤维化患者的丙型肝炎:治疗和持续病毒学应答对患者报告结果的影响

尽管治疗丙型肝炎病毒(HCV)感染的晚期肝病患者的必要性已被广泛接受,但治疗没有明显肝病的患者的益处尚不明确。我们的目的是评估在无纤维化或纤维化极少(Metavir分期F0–F1)的患者中治疗HCV对患者报告的结局(PROs)的影响。
更新日期:2017-12-20
down
wechat
bug